Krista J Hachey1, Christopher S Digesu1, Katherine W Armstrong1, Denis M Gilmore2, Onkar V Khullar3, Brian Whang1, Hisashi Tsukada1, Yolonda L Colson4. 1. Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass. 2. Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass; Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tenn. 3. Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass; Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Ga. 4. Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass. Electronic address: ycolson@partners.org.
Abstract
OBJECTIVE: To investigate safety and feasibility of navigational bronchoscopy (NB)-guided near-infrared (NIR) localization of small, ill-defined lung lesions and sentinel lymph nodes (SLN) for accurate staging in patients with non-small cell lung cancer (NSCLC). METHODS: Patients with known or suspected stage I NSCLC were enrolled in a prospective pilot trial for lesion localization and SLN mapping via NB-guided NIR marking. Successful localization, SLN detection rates, histopathologic status of SLN versus overall nodes, and concordance to initial clinical stage were measured. Ex vivo confirmation of NIR+ SLNs and adverse events were recorded. RESULTS: Twelve patients underwent NB-guided marking with indocyanine green of lung lesions ranging in size from 0.4 to 2.2 cm and located 0.1 to 3 cm from the pleural surface. An NIR+ "tattoo" was identified in all cases. Ten patients were diagnosed with NSCLC and 9 SLNs were identified in 8 of the 10 patients, resulting in an 80% SLN detection rate. SLN pathologic status was 100% sensitive and specific for overall nodal status with no false-negative results. Despite previous nodal sampling, one patient was found to have metastatic disease in the SLN alone, a 12.5% rate of disease upstaging with NIR SLN mapping. SLN were detectable for up to 3 hours, allowing time for obtaining a tissue diagnosis and surgical resection. There were no adverse events associated with NB-labeling or indocyanine green dye itself. CONCLUSIONS: NB-guided NIR lesion localization and SLN identification was safe and feasible. This minimally invasive image-guided technique may permit the accurate localization and nodal staging of early stage lung cancers.
OBJECTIVE: To investigate safety and feasibility of navigational bronchoscopy (NB)-guided near-infrared (NIR) localization of small, ill-defined lung lesions and sentinel lymph nodes (SLN) for accurate staging in patients with non-small cell lung cancer (NSCLC). METHODS:Patients with known or suspected stage I NSCLC were enrolled in a prospective pilot trial for lesion localization and SLN mapping via NB-guided NIR marking. Successful localization, SLN detection rates, histopathologic status of SLN versus overall nodes, and concordance to initial clinical stage were measured. Ex vivo confirmation of NIR+ SLNs and adverse events were recorded. RESULTS: Twelve patients underwent NB-guided marking with indocyanine green of lung lesions ranging in size from 0.4 to 2.2 cm and located 0.1 to 3 cm from the pleural surface. An NIR+ "tattoo" was identified in all cases. Ten patients were diagnosed with NSCLC and 9 SLNs were identified in 8 of the 10 patients, resulting in an 80% SLN detection rate. SLN pathologic status was 100% sensitive and specific for overall nodal status with no false-negative results. Despite previous nodal sampling, one patient was found to have metastatic disease in the SLN alone, a 12.5% rate of disease upstaging with NIR SLN mapping. SLN were detectable for up to 3 hours, allowing time for obtaining a tissue diagnosis and surgical resection. There were no adverse events associated with NB-labeling or indocyanine green dye itself. CONCLUSIONS: NB-guided NIR lesion localization and SLN identification was safe and feasible. This minimally invasive image-guided technique may permit the accurate localization and nodal staging of early stage lung cancers.
Authors: Matthew J Schuchert; Arman Kilic; Arjun Pennathur; Katie S Nason; David O Wilson; James D Luketich; Rodney J Landreneau Journal: Ann Thorac Surg Date: 2011-05-04 Impact factor: 4.330
Authors: Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: Valerie W Rusch; Debra Hawes; Paul A Decker; Sue Ellen Martin; Andrea Abati; Rodney J Landreneau; G Alexander Patterson; Richard I Inculet; David R Jones; Richard A Malthaner; Robbin G Cohen; Karla Ballman; Joe B Putnam; Richard J Cote Journal: J Clin Oncol Date: 2011-10-11 Impact factor: 44.544
Authors: Vivian E Strong; John Humm; Paul Russo; Achim Jungbluth; W Douglas Wong; Farhad Daghighian; Lloyd Old; Yuman Fong; Steven M Larson Journal: Surg Endosc Date: 2007-11-20 Impact factor: 4.584
Authors: Olugbenga T Okusanya; David Holt; Daniel Heitjan; Charuhas Deshpande; Ollin Venegas; Jack Jiang; Ryan Judy; Elizabeth DeJesus; Brian Madajewski; Kenny Oh; May Wang; Steven M Albelda; Shuming Nie; Sunil Singhal Journal: Ann Thorac Surg Date: 2014-08-05 Impact factor: 4.330
Authors: Christopher S Digesu; Krista J Hachey; Denis M Gilmore; Onkar V Khullar; Hisashi Tsukada; Brian Whang; Lucian R Chirieac; Robert F Padera; Michael T Jaklitsch; Yolonda L Colson Journal: J Thorac Cardiovasc Surg Date: 2017-12-14 Impact factor: 5.209